Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2002-04-17
2010-12-07
Krass, Frederick (Department: 1612)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S002600, C514S177000, C546S210000
Reexamination Certificate
active
07846957
ABSTRACT:
The use of at least one aromatase inhibitor in the production of a medicament for improving the implantation and pregnancy rates for a female undergoing assisted reproduction treatment, which comprises one or more daily doses of an aromatase inhibitor (AI) for administration during assisted reproduction cycles or ovarian stimulation cycles, wherein the doses of AI are selected from amounts effective to reduce serum estradiol levels. Also disclosed are related pharmaceutical preparations and packages.
REFERENCES:
patent: 4289762 (1981-09-01), Metcalf et al.
patent: 4728645 (1988-03-01), Browne
patent: 4845227 (1989-07-01), Hirsch et al.
patent: 4978672 (1990-12-01), Bowman et al.
patent: 6015789 (2000-01-01), Suzuki et al.
patent: 6953774 (2005-10-01), Palmer et al.
patent: 43 30 237 (1995-03-01), None
patent: 196 22 457 (1997-11-01), None
patent: 907 351 (1999-04-01), None
patent: WO-97/40846 (1997-11-01), None
patent: WO 9858657 (1998-12-01), None
Hamilton et al., “The third-generation non-steroidal aromatase inhibitors: A review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer.” Annals of Oncology 1999:10;377-384.
Homburg et al., “Low-dose FSH therapy for anovulatory infertility associated with polycystic ovary syndrome: rationale, results, reflections and refinements.” Human Reproduction Update 1999:5(5);493-499.
Mu et al., “Insulin Sensitizer, Troglitazine, Directly Inhibits Aromatase Activity in Human Ovarian Granulosa Cells.” Biochemical and Biophysical Research Communications 2000: 710-713.
Mitwally et al., “High ovulatory rates with use of Troglitazone in clomiphene-resistant women with polycystic ovary syndrome.” Human Reproduction 1999:14(11);2700-2703.
Dowsett, “Aromatase inhibitors come of age.” Annals of Oncology 1997:8;631-632.
Doldi et al., “Elevated serum progesterone on the day of HCG administration in IVF is associated with higher pregnancy rate in polycystic ovary syndrome.” Human Reproduction 1999:14(3);601-605.
DrugBank: DB00197 (Troglitazone) at http://www.drugbank.ca. Date: Jun. 13, 2005.
Adashi, “Clomiphene Citrate: Mechanism(s) and site(s) of Action—a Hypothesis Revisited,”Fertil Steril, vol. 42, No. 3, pp. 331-344 (1984).
Akhtar et al., “Mechanistic Studies on Aromatase and Related C-C Bond Cleaving P-450 Enzymes,”J. Steroid Biochem Mol Biol, vol. 44, pp. 375-387 (1993).
Archer et al., “Effects of Clomiphene Citrate on Episodic Luteinizing Hormone Secretion Throughout the Menstrual Cycle,”Am J. Obstet Gynecol, vol. 161, No. 3, pp. 581-589 (1989).
Basir et al., “Morphometric Analysis of Pen-Implantation Endometrium in Patients Having Excessively High Oestradiol Concentrations After Ovarian Stimulation,”Hum. Reprod., vol. 16, No. 3, pp. 435-440 (2001).
Bateman et al., “Exogenous Estrogen Therapy for Treatment of Clomiphene Citrate—Induced Cervical Mucus Abnormalities: Is It Effective?”Fertil Steril, vol. 54, pp. 577-579 (1990).
Ben-Ami et al., “Exogenous Estrogen Therapy Concurrent with Clomiphene Citrate—Lack of Effect on Serum Sex Hormone Levels and Endometrial Thickness,”Gynecol Obstet Invest, vol. 37, No. 3, pp. 180-182 (1994).
Cole et al., “Mechanism and Inhibition of Cytochrome P-450 Aromatase,”J. Med. Chem., vol. 33, pp. 2933-2944 (1990).
Coombes et al., “4-Hydroxyandrostenedione Treatment of Postmenopausal Patients with Advanced Breast Cancer,”The Lancet 2, pp. 1237-1239 (1984).
Dickey et al., “Observations on the Mechanism of Action of Clomiphene (MRL-41),”Fertil Steril, vol. 16, pp. 485-494 (1965).
Dowsett et al., “Vorozole Results in Greater Oestrogen Suppression Than Formestane in Postmenopausal Women and When Added to Goserella in Premenopausal Women with Advanced Breast Cancer,”Breast Cancer Research and Treatment, vol. 56, No. 1, pp. 25-34 (1999) (Abstract).
Fisch et al., “Unexplained Infertility: Evaluation of Treatment with Clomiphene Citrate and Human Chorionic Gonadotropin,”Fertil Steril, vol. 51, pp. 828-833 (1989).
Fluker et al., “Exogenous Gonadotropin Therapy in World Health Organization Groups I and II Ovulatory Disorders,”Obstet Gynecol, vol. 83, pp. 189-196 (1994).
Forman et al., “Evidence for an Adverse Effect of Elevated Serum Estradiol Concentration on Embryo Implantation,”Fertil Steril, vol. 49, pp. 118-121 (1988).
Garcia et al., “Advanced Endometrial Maturation After Ovulation Induction with Human Menopausal Gonadotropin/Human Chorionic Gonadotropin for in Vitro Fertilization,”Fertil Steril, vol. 41, pp. 31-35 (1984).
Garcia et al., “The Use of Clomiphene Citrate,”Fertil Steril, vol. 28, pp. 707-717 (1997).
Geisler et al., “Influence of Anastrozie (Arimidex), a Selective, Non-Steroidal Aromatase Inhibitor, on In Vitro Aromatisation and Plasma Oestrogen Levels in Postmenopausal Women with Breast Cancer,”Br J Cancer, vol. 74, pp. 1286-1291 (1996).
Gelety et al., “The Effect of Clomiphene Citrate and Menopausal Gonadotropins on Cervical Mucus in Ovulatory Cycles,”Fertil Steril, vol. 60, pp. 471-476 (1993).
Goldfarb et al., “Critical Review of 160 Clomiphene-related Pregnancies,”Obstet Gynecol, vol. 31, pp. 342-345 (1968).
Gonen et al., “Determination of an Adverse Effect of Clomiphene Citrate on Endometrial Growth,”Hum Reprod, vol. 5, pp. 670-674 (1990).
Graf et al., “Histologic Evaluation of the Luteal Phase in Women Following Follicle Aspiration for Oocyte Retrieval,”Fertil Steril, vol. 49, pp. 616-619 (1988).
Hadi et al., “Ovulation Induction and Endometrial Steroid Receptors,”Hum. Reprod., vol. 9, pp. 2405-2410 (1994).
Kettel et al., “Hypothalamic-pituitary-ovarian Response to Clomiphene Citrate in Women with Polycystic Ovary Syndrome,”Fertil Steril, vol. 59, No. 3, pp. 532-538 (1993).
Kolb et al., “Ultrastructural Characteristics of the Luteal Phase Endometrium in Patients Undergoing Controlled Ovarian Stimulation,”Fertil Steril, vol. 67, pp. 625-630 (1997).
Macrow et al., “Endometrial Structure After Superovulation: A Prospective Controlled Study,”Fertil Steril, vol. 61, pp. 696-699 (1994).
Mikkelson et al., “Single-dose Pharmacokinetics of Clomiphene Citrate in Normal Volunteers,”Fertil Steril, vol. 46, pp. 392-396 (1986).
Mitwally et al., “Aromatase Inhibition for Ovarian Stimulation: Future Avenues for Infertility Management,”Current Opinion in Obstetrics&Gynecology, vol. 14 (2002) (Abstract).
Mitwally et al., “Aromatase Inhibition Improves Ovarian Response to Follicle-Stimulating Hormone in Poor Responders,”Fertility&Sterility, vol. 77, pp. 776-780 (2002) (Abstract).
Mitwally et al., “Use of an Aromatase Inhibitor for Induction of Ovulation in Patients with an Inadequate Response to Clomiphene Citrate,”Fertil Steril, vol. 75, No. 2, pp. 305-309 (2001).
Nargund et al., “Cumulative Conception and Live Birth Rates in Natural (unstimulated) IVF Cycles,”Hum. Reprod., vol. 16, pp. 259-262 (2001).
Nebert et al., “The P-450 Superfamily: Update on New Sequences, Gene Mapping and Recommended Nomenclature,”DNA Mol. Biol., vol. 10, pp. 1-14 (1991).
Ng et al., “High Serum Oestradiol Concentration in Fresh IVF Cycles do not Impair Implantation and Pregnancy Rates in Subsequent Frozen-Thawed Embryo Transfer Cycles,”Hum. Reprod., vol. 15, pp. 250-255 (2000).
Noci et al., “Hormonal Patterns, Steroid Receptors and Morphological Pictures of Endometrium in Hyperstimulated IVF Cycles,”Eur. J. Obstet. Gynecol. Reprod. Biol., vol. 75, pp. 215-220 (1997).
Paulson et al., “Factors Affecting Embryo Implantation After Human In Vitro Fertilization: A Hypothesis,”Am J Obstet Gynecol, vol. 163, pp. 2020-2023 (1990).
Randall et al.,
Casper Robert F.
Mitwally Mohamed F. M.
Ares Trading S.A.
Krass Frederick
Marshall & Gerstein & Borun LLP
Webb Walter E
LandOfFree
Aromatase inhibition to enhance assisted reproduction does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Aromatase inhibition to enhance assisted reproduction, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aromatase inhibition to enhance assisted reproduction will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4185204